Search Bar & Filters
Found 971 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a new hospital incubator pad that provides stochastic vibrotactile stimulation SVS as a complementary treatment for apnea of prematurity AOP, a common condition in preterm infants where breathing stops for 20 seconds or more. This study aims to establish the safety, effectiveness, and clinical risks and benefits of this device, which could improve management of AOP beyond the current standard therapy of caffeine citrate. The study focuses on newborns born before 33 weeks gestational age and younger than 38 weeks postmenstrual age at enrollment. The study compares two groups one receiving standard therapy with caffeine citrate plus continuous SVS stimulation via the Prapela SVS incubator pad, and a control group receiving standard therapy with an inert pad that looks identical but does not vibrate. Treatment with the SVS pad continues until the infant is apnea-free for three days and less than two weeks from anticipated discharge, or until the clinician decides to stop. If apnea returns after stopping, treatment may be restarted. Follow-up surveys will be conducted by telephone at 1 and 2 years of age to assess neurological development. Participants will be monitored closely with clinical evaluations and questionnaires completed by clinicians to assess risks and benefits. The primary outcome is the change in apnea rate during 7 to 28 days of intervention, with secondary outcomes assessed at earlier time points. The study is randomized and single-masked, with safety and efficacy data gathered to support possible FDA clearance and future use of the SVS incubator pad as an adjunctive therapy to improve outcomes in preterm infants with AOP.
Actively Recruiting
Researchers are evaluating CGT9486 bezuclastinib in an open-label Phase 2 study for patients with Advanced Systemic Mastocytosis AdvSM, including Aggressive Systemic Mastocytosis ASM, Systemic Mastocytosis with an Associated Hematologic Neoplasm SM-AHN, and Mast Cell Leukemia MCL. The study aims to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of bezuclastinib as a single agent in these conditions. Participants receive bezuclastinib tablets orally, taken continuously in 28-day cycles. The study has two parts Part I focuses on identifying clinically active and tolerable doses of bezuclastinib, while Part II determines the drugs efficacy by measuring the modified IWG Objective Response Rate ORR and confirming the exposure-response relationship. Treatment and evaluation continue for up to 18 months. During the study, participants undergo assessments including laboratory tests, imaging to measure spleen and liver volume, and evaluation of mutation allele burden, serum tryptase, and histopathologic changes in blood and bone marrow. Safety is monitored through adverse event reporting. The study measures duration and time to response, progression-free survival, and overall survival. Participants are involved in regular monitoring throughout the treatment period extending up to 18 months.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of elenestinib BLU-263 combined with symptom directed therapy SDT compared to placebo plus SDT in adults with indolent systemic mastocytosis ISM whose symptoms are not well controlled by SDT alone. This Phase 23 randomized, double-blind, placebo-controlled study includes participants from Parts 1 and 2 with ISM, with those in Part 2 continuing into Part 3 for open-label elenestinib treatment. Part K enrolls participants with prior use of selective KIT inhibitors, and additional pharmacokinetic groups will also participate. Participants receive SDT tailored individually and take either oral elenestinib or matching placebo once daily. In Part 1, treatment continues until study completion, while Part 2 involves approximately 48 weeks of dosing. Part 3 and other parts may extend treatment up to about 5 years. The study monitors participants throughout these periods, with dosing and symptom management adjusted as needed. During the study, participants undergo various assessments including symptom scoring with the Indolent Systemic Mastocytosis-Symptom Assessment Form ISM-SAF, safety monitoring for adverse events, and laboratory tests such as serum tryptase levels and KIT D816V allele fraction. Bone marrow mast cells, bone mineral density, and quality of life measures are also evaluated. Researchers track these outcomes at multiple timepoints from baseline up to 5 years to understand treatment impact and participant safety.
Actively Recruiting
Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and early effects of 4D-710, an investigational gene therapy, in adults with cystic fibrosis CF lung disease who cannot use or tolerate existing CFTR modulator therapies. A sub-study also includes adults with advanced CF lung disease or frequent lung flare-ups who are currently on CFTR modulator therapy. This Phase 12 open-label trial aims to find appropriate dosing and assess potential benefits for these patient groups. Participants receive a single inhaled dose of 4D-710, which is a gene therapy designed to deliver a corrected version of the CFTR gene to lung cells. The study includes a dose exploration phase for those ineligible for modulator therapy, a dose expansion phase at selected doses, and a sub-study for participants on modulator therapy receiving various doses. Each participant undergoes one administration of the therapy during the trial. Throughout the study, participants are monitored for adverse events over a 60-month period. Evaluations include lung function tests, oxygen saturation measurements, and tracking of pulmonary exacerbations. Participants maintain their existing treatments if applicable, and researchers assess safety and early signs of effectiveness. The total study duration extends up to approximately nine years, including long-term observation after dosing.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the use of psilocybin, a 5-HT2A receptor agonist, for helping adults with tobacco use disorder quit smoking. This phase 2, multi-site, double-blind, randomized clinical trial involves 66 participants across four experienced research sites. The study aims to compare psilocybin with niacin, an active placebo, both combined with cognitive behavior therapy CBT, to assess smoking cessation effectiveness and related cognitive changes over 12 months. Participants will be randomly assigned to receive either oral psilocybin or oral niacin in two sessions spaced one week apart. Psilocybin doses are 30 mg in the first session and either 30 mg or 40 mg in the second, depending on responses to a mystical experience questionnaire. Niacin doses are 150 mg in the first session and either 150 mg or 200 mg in the second, following the same dosing schedule. Both groups receive CBT alongside the medication sessions to support quitting smoking. During the study, participants will undergo assessments including cognitive control tasks and questionnaires about smoking urges at screening and shortly after a target quit date. Smoking abstinence will be biochemically confirmed and measured for up to 12 months. Safety and health status will be monitored through interviews, physical exams, ECGs, and lab tests. The trial also investigates psychological factors that may influence quitting success, with overall participation lasting about one year.
Actively Recruiting
Researchers are evaluating remibrutinib, an oral medication, in a Phase III clinical trial involving adolescents and adults aged 12 to 65 with IgE-mediated allergies to peanut, cows milk cooked and uncooked, or hens egg cooked and uncooked. The study compares remibrutinib to a placebo to assess its safety and effectiveness in managing these food allergies. Participants are divided into four sub-studies based on their specific allergy peanut, milk, egg, or a combination of these allergens. During the initial treatment period, participants receive either remibrutinib or placebo for up to 24 weeks in the first three sub-studies, and up to 4 weeks in the fourth sub-study. After this, all participants enter an open-label phase where they receive remibrutinib until Week 52. Following this period, eligible participants can join a separate open-label post-trial study to evaluate long-term effects, while others enter a 4-week safety follow-up without treatment. Throughout the study, participants undergo regular assessments including allergen challenges to measure tolerance to specific amounts of allergen proteins at Weeks 4 and 24, depending on the sub-study. Safety is monitored by recording any adverse events up to 56 weeks. Participants are asked to avoid exposure to their allergens and complete skin prick tests, blood tests for allergen-specific IgE, and double-blind placebo-controlled food challenges. The trial duration is 52 weeks with additional follow-up for some participants.
Actively Recruiting
Researchers are evaluating the use of delgocitinib cream applied twice daily to treat adults with mild to severe lichen sclerosus LS, focusing mainly on female participants since LS is more common in females. This Phase 3 trial is designed to assess the efficacy and safety of delgocitinib in comparison to a cream vehicle over a long period. The study includes two parts Part 1 enrolls females to determine the best dose, and Part 2 enrolls both males and females to further evaluate safety and efficacy. Participants will be assigned randomly to receive either delgocitinib cream at specified doses or a cream vehicle. Treatments are applied twice daily during an initial 12-week period followed by a continuation treatment period lasting 40 weeks. Various dosing regimens are used across groups, including delgocitinib cream alone, cream vehicle alone, or combinations transitioning between the two during the study. Male participants will be included in a substudy to evaluate delgocitinibs effects in men. During the trial, participants will attend clinic visits and undergo assessments including measurement of skin condition severity using the IGA-LS score, clinical lichen sclerosus score CLISSCO, and patient-reported scales for skin pain and itch. Quality of life related to vulvar symptoms will also be monitored. Safety is carefully tracked through adverse event reporting and laboratory tests throughout the study, which lasts from 55 to 60 weeks per participant. The primary outcome is the number of participants achieving a specific improvement in LS severity at week 12.
Actively Recruiting
Opioid overdose deaths have reached historically high levels in the United States, especially among patients discharged from emergency departments ED. This study evaluates a bundled intervention designed to increase treatment uptake, reduce repeat opioid overdoses, and prevent overdose deaths in patients with opioid use disorder OUD who have recently experienced nonfatal overdoses. The intervention is tested in a Phase 4 randomized trial comparing it to usual care in patients discharged from the same ED. Participants are randomly assigned to either the experimental group receiving a bundled intervention or to a usual care group. The bundled intervention includes peer support specialists who meet patients before ED discharge, scheduled telehealth contacts, and physician-led buprenorphine treatment via telehealth for 12 weeks. After this period, participants get assistance linking to long-term community addiction treatment. The usual care group receives standard ED care including buprenorphine initiation and a list of treatment programs but no further intervention. Throughout the study, participants complete baseline and follow-up surveys at 1 and 3 months via electronic links with reminders. Researchers monitor treatment retention, adherence to buprenorphine, connection to addiction programs, repeat overdoses, hospital revisits, peer support contact adherence, and opioid overdose deaths. Secondary measures include questionnaires on trauma, overdose risk, satisfaction, anxiety, depression, craving, and sleep quality. The trial runs until 2030 with the goal of informing broader implementation strategies.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a study drug called LY4065967 for treating chronic low back pain CLBP. This trial is part of a larger master protocol aimed at speeding up the development of new treatments for chronic pain conditions. The study focuses on adults with a history of low back pain lasting at least three months. Participants will be randomly assigned to receive either LY4065967 or a placebo, both given orally. The study uses a double-blind design, meaning neither the participants nor the researchers know who receives the study drug or placebo. The treatment phase lasts for 8 weeks, during which participants take the assigned medication regularly. During the study, participants will be assessed at the start and at week 8 for changes in pain intensity using a numeric rating scale. Other evaluations include overall improvement, worst pain intensity, sleep quality, emotional functioning, use of rescue medication, and disability related to back pain. The trial includes safety monitoring and will continue until April 2027, with visits scheduled to track these outcomes.
1-10 of 971
1